Core Viewpoint - The company has successfully administered the first dose of its self-developed radiolabeled drug, 177Lu-PSMA-3D1015 (3D1015), to a patient, marking a significant milestone in its clinical research for treating PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) [1] Group 1: Clinical Research Focus - The study specifically targets patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) [1] - The research will systematically evaluate the core clinical value of 3D1015, focusing on the drug's safety and radiation dosimetry assessment [1] - The study aims to collect in-depth pharmacokinetic characteristics and dose exploration data of the drug in humans, providing direct clinical evidence for dose determination and risk control in subsequent registration clinical trials [1]

Core Viewpoint - The company has successfully administered its first self-developed radiopharmaceutical drug, 177Lu-PSMA-3D1015 (3D1015), to a patient, marking a significant milestone in its clinical research for treating PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) [1] Group 1: Clinical Research - The study focuses on evaluating the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive mCRPC [1] - The research aims to systematically assess the core clinical value of 3D1015, emphasizing drug safety and dosimetry evaluation [1] - The study will collect in-depth pharmacokinetic characteristics and dose exploration data to provide direct clinical evidence for dose determination and risk control in subsequent registration clinical trials [1]

Core Viewpoint - The company has successfully administered the first dose of its self-developed radiopharmaceutical drug, Lu-PSMA-3D1015 ("3D1015"), to a patient, marking a significant milestone in its clinical research for treating PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) [1] Group 1: Clinical Research - The study focuses specifically on patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) [1] - The research aims to systematically evaluate the core clinical value of 3D1015, emphasizing the drug's safety and radiation dosimetry assessment [1] - The study will collect in-depth pharmacokinetic characteristics and dose exploration data of the drug in humans, providing direct clinical evidence for dose determination and risk control in subsequent registration clinical trials [1]

自願公告 新型放射性核素偶聯藥物3D1015首次人體給藥成功 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 3D Medicines Inc. 思路迪医药股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1244） 本公司無法確保能成功開發及商業化3D1015。本公司股東及潛在投資者在買賣本 公司股份時務請審慎行事。 承董事會命 思路迪医药股份有限公司 董事長兼執行董事 龔兆龍博士 香港，2025年8月28日 於本公告日期，本公司董事會成員包括執行董事龔兆龍博士，非執行董事朱晉橋 先生、周峰先生及陳雅雯女士，及獨立非執行董事李靖博士、連達鵬博士及劉信 光先生。 董事會欣然宣布，本公司首款自主研發的放射性核素偶聯藥物 (RDC)177Lu-PSMA-3D1015（「3D1015」）已成功完成首例患者給藥。本研究旨在評 估3D1015用於PSMA陽性轉移性去勢抵抗性前列腺癌(mCRPC)患者的安全性與初 步療效。 該研究人群精準聚焦於PSMA ...

Core Viewpoint - The collaboration between 思路迪医药 and 楷拓生物 aims to enhance the development of mRNA-based therapies by leveraging their respective strengths in AI-driven mRNA research and large-scale mRNA production [1] Group 1: Strategic Collaboration - 思路迪医药 has entered into a strategic cooperation framework agreement with 楷拓生物, focusing on the integration of their technologies in mRNA research and delivery systems [1] - The partnership will utilize 思路迪医药's proprietary AI+mRNA research platform and lipid nanoparticle (LNP) delivery system alongside 楷拓生物's expertise in mRNA production [1] Group 2: Technological Advancements - 思路迪医药 has established a globally recognized mRNA technology platform and LNP delivery system, which are crucial for the development of innovative therapies [1] - The mRNA technology platform includes a multi-module tumor vaccine analysis system (3D-PreciseAg) that supports extensive antigen multi-omics analysis and selection of tumor antigens [1] - The AI-enhanced LNP delivery technology platform allows for the screening of thousands of compounds, resulting in the synthesis of various LNP products tailored for different delivery scenarios, improving the efficiency and targeting of mRNA tumor vaccines and immune cell therapies [1]

Core Viewpoint - The announcement highlights a strategic cooperation agreement between Sillodic Pharmaceuticals and Kaito Bio, focusing on the development of mRNA-based therapies utilizing Sillodic's proprietary AI+mRNA research platform and lipid nanoparticle delivery system [1] Group 1: Strategic Cooperation - Sillodic Pharmaceuticals entered into a strategic cooperation framework agreement with Kaito Bio on August 20, 2025 [1] - The collaboration aims to leverage Sillodic's self-developed AI+mRNA research platform and lipid nanoparticle delivery system (3D-LNP) alongside Kaito Bio's expertise in large-scale mRNA production [1] - The partnership will enhance cooperation in targeted LNP delivery (tLNP), tumor vaccines, and in vivo CAR-T/NK therapies, with specific implementations to follow in formal agreements [1] Group 2: Technological Advancements - Sillodic Pharmaceuticals has established a globally recognized mRNA technology platform and LNP delivery system [1] - The mRNA technology platform is built on advanced AI technology, featuring a multi-module tumor vaccine analysis platform (3D-PreciseAg) that supports extensive antigen multi-omics analysis and optimal tumor antigen selection [1] - The AI-enhanced LNP delivery technology platform allows for the screening of thousands of compounds through AI algorithms, resulting in various LNP products that improve delivery efficiency and targeting of mRNA tumor vaccines and in vivo CAR-T/NK therapies while significantly reducing toxicity [1]

Group 1 - The core viewpoint of the news is that Sidodi Pharmaceutical has entered into a strategic cooperation framework agreement with Kaito Bio to enhance their collaboration in the mRNA field, leveraging their respective strengths in AI+mRNA research and large-scale mRNA production [1] - The collaboration will focus on targeted LNP delivery, tumor vaccines, and in vivo CAR-T/NK therapies, indicating a significant step in Sidodi Pharmaceutical's commitment to mRNA research and development [1] - This partnership aims to provide robust capacity support for the clinical development and future commercialization of innovative therapies based on mRNA-LNP technology [1] Group 2 - Sidodi Pharmaceutical has established a globally recognized mRNA technology platform and LNP delivery system, which is built on advanced AI technology [2] - The mRNA technology platform includes a multi-module tumor vaccine analysis platform (3D-PreciseAg) that supports extensive antigen multi-omics analysis and the selection of tumor antigens [2] - The company possesses an AI-enhanced LNP delivery technology platform that utilizes AI algorithms to screen thousands of compounds, improving the delivery efficiency and targeting of mRNA tumor vaccines and in vivo CAR-T/NK therapies while significantly reducing toxicity [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 3D Medicines Inc. 思路迪医药股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1244） 本公司欣然宣布，思路迪醫藥於2025年8月20日與楷拓生物訂立戰略合作框架協 議（「該協議」）。 根據該協議，雙方將基於思路迪醫藥的自研具有自有知識產權的AI+mRNA研發 平台和脂質體遞送系統(3D-LNP)，與楷拓生物的mRNA規模化生產優勢和經驗， 深化靶向LNP遞送(tLNP)、腫瘤疫苗、in vivo CAR-T/NK等領域的合作。具體實 施將依據後續正式協議落實。此次合作標誌着思路迪醫藥正不斷加速布局mRNA 領域研究，為基於mRNA-LNP技術的創新療法產品後續臨床開發以及未來商業化 提供堅實的產能保障。 思路迪醫藥目前已建立起擁有全球自主知識產權的mRNA技術平台及LNP遞送系 統平台。該mRNA技術平台是基於目前先進的AI技術構建的多模塊腫瘤疫苗分析 平台(3D-Pre ...

董事會會議召開日期 思路迪医药股份有限公司（「本公司」）董事會（「董事會」）宣佈，本公司將於2025 年8月29日（星期五）舉行董事會會議，藉以（其中包括）批准本公司及其附屬公司 截至2025年6月30日止六個月的未經審核之中期業績公告，以及考慮派發中期股 息（如有）。 承董事會命 思路迪医药股份有限公司 董事長兼執行董事 龔兆龍博士 香港，2025年8月19日 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 3D Medicines Inc. 思路迪医药股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1244） 於本公告日期，本公司董事會成員包括執行董事龔兆龍博士，非執行董事朱晉橋 先生、周峰先生及陳雅雯女士，及獨立非執行董事李靖博士、連達鵬博士及劉信 光先生。 ...

Group 1 - The majority of Hong Kong biotech stocks experienced declines, with notable drops in several companies [1] - Specifically, Gilead Sciences fell by 15.06%, while Yunkang Group and Pigeon BioPharma dropped over 14% and 9% respectively [2] - Other companies such as China Antibody and Jiahua Bio also saw declines exceeding 7% [1][2] Group 2 - The latest market prices and total market capitalizations for the affected companies include: - Gilead Sciences at 15.510 with a market cap of 14.946 billion - Yunkang Group at 2.300 with a market cap of 1.429 billion - Pigeon BioPharma at 31.760 with a market cap of 12.258 billion - Tengsheng BioPharma at 2.210 with a market cap of 1.590 billion - China Antibody at 3.210 with a market cap of 4.371 billion - Jiahua Bio at 4.460 with a market cap of 2.347 billion [2]